NCT06780683View on ClinicalTrials.gov

Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease

RecruitingOBSERVATIONAL
Enrollment

174

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative Colitis
Interventions
DRUG

Upadacitinib

"Induction Therapy: The dose of upadacitinib for induction therapy is 45mg once daily for a duration of 8 weeks (for ulcerative colitis) or 12 weeks (for Crohn's disease).~Maintenance Therapy: The dose of upadacitinib for maintenance therapy is 15mg once daily; for patients with refractory, severe, or extensive disease, a maintenance dose of 30mg once daily may be considered."

Trial Locations (6)

510000

RECRUITING

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou

510655

RECRUITING

Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou

514000

RECRUITING

Meizhou People's Hospital, Meizhou

518000

RECRUITING

The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen

530000

RECRUITING

Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning

545000

RECRUITING

Liuzhou People's Hospital, Liuzhou

All Listed Sponsors
lead

Xiang Gao

OTHER